The European market has recently experienced modest gains amidst easing geopolitical tensions and strong corporate earnings, though it faces pressure from potential U.S. tariff increases. In this environment, identifying undervalued stocks can be particularly rewarding as they may offer significant growth potential when the market stabilizes or improves.

As European markets navigate a landscape of interest rate assessments and trade uncertainties, the pan-European STOXX Europe 600 Index remains relatively stable, with major indexes like Italy's FTSE MIB and Germany's DAX showing modest gains. In this environment, identifying stocks that are potentially undervalued can offer intriguing opportunities for investors seeking to capitalize on discrepancies between market prices and intrinsic value estimates.

Thinking about what to do with your GL Events shares? Whether you are sizing up an entry point or reassessing your position after a strong rally, now is a great time to take stock of what is really happening beneath the surface. GL Events is one of those names where, if you had blinked a year ago, you might have missed some serious upside. Over the past five years, the stock has delivered a remarkable 219.9% return, and it is up 103.9% over three years alone. Even with a recent pullback of...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.